GlassScriptPhysician profile
Pedro O Diaz
NPI 1578532800
$78,080.08
in general payments reported to CMS, 2019-2025
29 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,963 · 2020: $14K · 2021: $52K · 2022: $5,745 · 2023: $902 · 2024: $1,116 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $66,898.48 | 2020-2025 | Nexletol |
| Biotronik INC. | $4,169.35 | 2019-2023 | Solia, Acticor 7 Vr-T Dx |
| Abbott Laboratories | $1,267.69 | 2019-2024 | Navitor |
| Novartis Pharmaceuticals Corporation | $1,135.59 | 2019-2025 | |
| Pfizer INC. | $653.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $481.25 | 2019-2025 | Eliquis, Camzyos |
| Atricure, INC. | $410.87 | 2023 | |
| Sanofi-Aventis U.S. LLC | $350.59 | 2019-2024 | |
| Medtronic, INC. | $345.89 | 2021-2024 | Pulseselect |
| Surmodics, INC. | $343.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $319.60 | 2019-2025 | Wainua, Lokelma, Farxiga |
| Edwards Lifesciences Corporation | $246.96 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $244.87 | 2019-2020 | |
| Amgen INC. | $160.56 | 2024-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $148.08 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $127.97 | 2019 | |
| Impulse Dynamics (USA) INC. | $127.01 | 2023-2024 | Optimizer, Optimizer |
| Lexicon Pharmaceuticals, INC. | $92.68 | 2023-2024 | Inpefa |
| Xeris Pharmaceuticals, INC. | $89.70 | 2022-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $72.50 | 2025 | Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $70.13 | 2025 | |
| Arbor Pharmaceuticals, INC. | $68.59 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $64.09 | 2023-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $62.29 | 2024 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $39.25 | 2019 | |
| Exact Sciences Corporation | $25.00 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $23.85 | 2024 | Verquvo |
| Scpharmaceuticals INC. | $21.77 | 2024 | |
| Philips North America LLC | $17.75 | 2025 | Ecc Solutions |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.